Advertisement
Singapore markets closed
  • Straits Times Index

    3,322.62
    +14.72 (+0.45%)
     
  • S&P 500

    5,313.87
    +6.86 (+0.13%)
     
  • Dow

    39,388.00
    -283.04 (-0.71%)
     
  • Nasdaq

    16,909.09
    +107.55 (+0.64%)
     
  • Bitcoin USD

    68,087.31
    -1,871.23 (-2.67%)
     
  • CMC Crypto 200

    1,467.16
    -35.50 (-2.36%)
     
  • FTSE 100

    8,341.87
    -28.46 (-0.34%)
     
  • Gold

    2,344.90
    -48.00 (-2.01%)
     
  • Crude Oil

    77.48
    -0.09 (-0.12%)
     
  • 10-Yr Bond

    4.4910
    +0.0570 (+1.29%)
     
  • Nikkei

    39,103.22
    +486.12 (+1.26%)
     
  • Hang Seng

    18,868.71
    -326.89 (-1.70%)
     
  • FTSE Bursa Malaysia

    1,629.18
    +7.09 (+0.44%)
     
  • Jakarta Composite Index

    7,222.38
    +36.34 (+0.51%)
     
  • PSE Index

    6,659.99
    +52.77 (+0.80%)
     

Wall Street Says This Growth Stock Is a Buy, but Is It Overvalued?

Wall Street Says This Growth Stock Is a Buy, but Is It Overvalued?

A struggling economy and a bear market haven't been able to stop Vertex Pharmaceuticals (NASDAQ: VRTX). Vertex's forward multiple comes in at more than four times the upper bounds of this range. Also, the company's forward price-to earnings (P/E) multiple is higher than that of the biotech industry, which is currently about 15.